Denver - The PETA International Science Consortium, Ltd., will present at the annual meeting of the Society for Risk Analysis on a framework for optimizing nonanimal testing methods for nanomaterials. This presentation builds upon a talk given at September's Nano-Risk Analysis II workshop, co-sponsored by the PETA International Science Consortium Ltd.
Dr. Amy Clippinger, science advisor for the Science Consortium, will discuss exposure considerations that need to be addressed in order to optimize nonanimal testing strategies for human health risk assessment in Denver, December 8-10.
The growing use of nanomaterials in consumer products has increased human exposure to these materials. Nanomaterials undergo many transformations between the time they are manufactured and the time humans are exposed, and thus it is critical to thoroughly characterize and test nanomaterials not only in their manufactured form but to examine them in the form that is most relevant to human exposure.
Says Dr. Clippinger, "It is important to understand the means by which humans may be exposed to a nanomaterial so that in vitro systems can be designed to mimic a realistic exposure. For example, in order to mimic the human situation, a material that is most likely to be inhaled would be coated in a physiologically relevant fluid, such as lung surfactant, and tested using human lung cells grown at the air-liquid interface. Furthermore, it is critical to design testing strategies to incorporate in vitro methods in a risk assessment-based paradigm that can be applied by regulators to make intelligent decisions regarding the safety of nanomaterials."
For additional information on the PETA International Science Consortium, please see http://www.